Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues

Upsala Journal of Medical Sciences

Volumn 119, Issue 1, 2014, Pages 19-24

  Rong, Minhua ^a   He, Rongquan ^a   Dang, Yiwu ^a   Chen, Gang ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Metastasis; MiR 146a; Oncogenes; Paraffin embedded tissues; Pathology; RT qPCR; Tumor biology

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MIRN146 MICRORNA, HUMAN; PRIMER DNA;

ARTICLE; FEMALE; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

BASE SEQUENCE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; DNA PRIMERS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84894038930     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2013.856970     Document Type: Article

References (49)

1. Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis. Dig Dis. 2011;29:284-8.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94: 153-6.
3. Liu B, Mao A, Liu D. The hypothesis of an effective strategy for resistance of hepatocellular carcinoma to therapyautophagy. West Indian Med J. 2011;60:666-8.
4. Kudo M. Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology. 2011;81:1-10.
5. Meguro M, Mizuguchi T, Kawamoto M, Hirata K. The molecular pathogenesis and clinical implications of hepatocellular carcinoma. Int J Hepatol. 2011;2011:818672.
6. Zemel R, Issachar A, Tur-Kaspa R. The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis. 2011;15:261-79; vii-x.
7. Vertemati M, Moscheni C, Petrella D, Lamperti L, Cossa M, Gambacorta M, et al. Morphometric analysis of hepatocellular nodular lesions in HCV cirrhosis. Pathol Res Pract. 2012;208: 240-4.
8. Abdo AA, Al-Ahdal MN, Khalid SS, Helmy A, Sanai FM, Alswat K, et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int. 2013;7:533-8.
9. Hu L, Chen G, Yu H, Qiu X. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int. 2010;4:423-32.
10. Chen G, Luo D. Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India. 2008;21:275-8.
11. Chen G, Dang YW, Luo DZ, Feng ZB, Tang XL. Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res. 2008;17: 183-9.
12. Chen G, LuoDZ, Liu L, Feng ZB, Guo F, Li P.Hepatic local micro-environmental immune status in hepatocellular carcinoma and cirrhotic tissues. West Indian Med J. 2006;55: 403-8.
13. Chen G, Luo D. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med Sci. 2008;113:297-304.
14. Yang M, Chen G, Dang Y, Luo D. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci. 2010;115:232-7.
15. Ruan ZP, Xu R, Lv Y, Tian T, Wang WJ, Guo H, et al. PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. Oncol Res. 2012;20:113-21.
16. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047-63.
17. Winter J, Diederichs S. MicroRNA biogenesis and cancer. Methods Mol Biol. 2011;676:3-22.
18. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 2011; 10:38.
19. Omelia EJ, Uchimoto ML, Williams G. Quantitative PCR analysis of blood- and saliva-specific microRNA markers following solid-phase DNAextraction. Anal Biochem. 2013;435: 120-2.
20. Hui A, How C, Ito E, Liu FF. Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer. 2011;11:500.
21. Di Leva G, Briskin D, Croce CM. MicroRNA in cancer: new hopes for antineoplastic chemotherapy. Ups J Med Sci. 2012; 117:202-16.
22. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer. 2010;46:298-311.
23. Siegrist F, Singer T, Certa U. MicroRNA expression profiling by bead array technology in human tumor cell lines treated with interferon-alpha-2a. Biol Proced Online. 2009;11:113-29.
24. Papagiannakopoulos T, Kosik KS. MicroRNAs: regulators of oncogenesis and stemness. BMC Med. 2008;6:15.
25. Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, et al. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 2012;32:772-82.
26. Negrini M, Gramantieri L, Sabbioni S, Croce CM. MicroRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem. 2011;11:500-21.
27. Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS ONE. 2011;6:e16435.
28. Diao S, Zhang JF, Wang H, He ML, Lin MC, Chen Y, et al. Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma. Proteomics. 2010;10:3723-31.
29. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, et al. MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 2010;6:402.
30. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond). 2011;120:183-93.
31. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR- 146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2013;52: 297-303.
32. Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, et al. MiR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS ONE. 2013;8:e60317.
33. Dang Y, Luo D, Rong M, Chen G. Underexpression of miR- 34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PLoS ONE. 2013;8:e61054.
34. Rong M, Chen G, Dang Y. Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer. 2013; 13:21.
35. Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.
36. Zhu K, Pan Q, Zhang X, Kong LQ, Fan J, Dai Z, et al. MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis. 2013;34:2071-9.
37. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18:997-1006.
38. Brase JC, Wuttig D, Kuner R, Sultmann H. Serum micro- RNAs as non-invasive biomarkers for cancer. Mol Cancer. 2010;9:306.
39. Hu M, Zhao L, Hu S, Yang J. The association between two common polymorphisms in MicroRNAs and hepatocellular carcinomariskinAsianpopulation. PLoSONE.2013;8:e57012.
40. Wang Z, Cao Y, Jiang C, Yang G, Wu J, Ding Y. Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS ONE. 2012;7:e40039.
41. Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008;29:2126-31.
42. Morgan CP, Bale TL. Sex differences in microRNA regulation of gene expression: no smoke, just miRs. Biol Sex Differ. 2012;3:22.
43. Lin SL, Chiang A, Chang D, Ying SY. Loss of mir-146a function in hormone-refractory prostate cancer. RNA. 2008; 14:417-24.
44. Hou Z, Yin H, Chen C, Dai X, Li X, Liu B, et al. MicroRNA-146a targets the L1 cell adhesion molecule and suppresses the metastatic potential of gastric cancer. MolMed Report. 2012;6:501-6.
45. Xiao B, Zhu ED, Li N, Lu DS, Li W, Li BS, et al. Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. Oncol Rep. 2012;27:559-66.
46. Mei J, Bachoo R, Zhang CL. MicroRNA-146a inhibits glioma development by targeting Notch1. Mol Cell Biol. 2011;31: 3584-92.
47. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NFkappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008;27:5643-7.
48. Li Y, Vandenboom TG II. Wang Z, Kong D, Ali S, Philip PA, et al. MiR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010;70:1486-95.
49. XuB,WangN,WangX,TongN,ShaoN,TaoJ, et al.MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castrationresistant prostate cancer. Prostate. 2012;72:1171-8.